The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68
about
Phosphorylated p68 RNA helicase activates Snail1 transcription by promoting HDAC1 dissociation from the Snail1 promoterT-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?Tumor neoantigens: building a framework for personalized cancer immunotherapyDEAD-box RNA helicase subunits of the Drosha complex are required for processing of rRNA and a subset of microRNAsPhotodynamic therapy of tumors can lead to development of systemic antigen-specific immune responseGenetic basis for clinical response to CTLA-4 blockade in melanomaRelapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinityIdentification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide.The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes.Contribution of mass spectrometry to contemporary immunology.CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression.Contributions of mass spectrometry to structural immunology.Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.Role of TGF-beta in immune-evasion of cancer.Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects.Assumptions of the tumor 'escape' hypothesis.Stimulation of anti-tumor immunity by photodynamic therapyThe immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein.Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genesExpression of tumour-specific antigens underlies cancer immunoeditingImmune recognition of self in immunity against cancer.Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo.Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens.Prediction of treatment efficacy for prostate cancer using a mathematical model.Neoantigen: A Long March toward Cancer ImmunotherapyTumor-associated fibroblasts predominantly come from local and not circulating precursorsSpecificity in cancer immunotherapy.Lack of immunoediting in murine pancreatic cancer reversed with neoantigen.Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.Spleen cells from young but not old immunized mice eradicate large established cancers.Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges.Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice.Targeting cancer-specific mutations by T cell receptor gene therapy.The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.Arf tumor suppressor disrupts the oncogenic positive feedback loop including c-Myc and DDX5.Applications of Immunogenomics to Cancer.'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.The "Achilles Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies.
P2860
Q24294150-7F9DBCE2-1FFE-4DFC-8256-879B92C7DDFFQ27335110-B33E4FBA-8D33-4A2E-8139-3DA064B6134DQ28082704-E94542C6-D1B4-4A84-B9F1-8949B5EB396DQ28589022-FD73A0C5-D0EF-4162-928F-8F10D33EC02FQ28744245-1F126CFC-3CD5-46E6-8DA0-53D46B81F979Q29620594-6CF54197-CD3E-4D0F-90B3-87D9B3112E5BQ30413827-EB211529-E9A7-45E3-AC20-7601FAFC8022Q30436422-21BDD411-B2B5-49F2-8717-ABFC1AF1B5F9Q30444065-F2149282-9D30-4677-AC47-912B25AA6C18Q30697033-3B079C3B-9B99-4330-ACFE-18F1E4931143Q33808334-40E11159-4FD7-4A3D-BD5D-324426DF5DE9Q33837085-E1302B3E-2F84-45F3-AE40-7434AE0DE33EQ33854515-46054993-CC5B-4539-9021-FFE0FB9EBBD2Q33910650-3A5D78F7-D788-4ECD-9423-CFB33EE2D268Q33917224-D1DEC0E3-A39E-499F-AEA9-9BCE03AF4038Q34136492-4C58AFB8-A437-4192-94D3-18FB7A851DE4Q34429312-C038D68F-1F5D-4C48-88D9-F225AD1E10C1Q34583258-9FE6A0AB-65DD-435E-8FED-F342D83D6D7DQ34697795-B7708340-9ECA-4153-9DB3-637D7FBC1FD7Q35049933-7454A29F-1D46-46D4-87B2-9B04D925BB88Q35079913-59EBA997-FC00-4343-B031-B65EADB01C13Q35785378-BBAF8815-C74E-4031-BB9B-0BE0C2BC1AF4Q35864865-62922B3C-B15A-47C8-A4A2-29D708F32AB8Q36367821-89BDAB32-45EF-470E-BEF5-DCF7B3ADB5A3Q36369462-2C694A99-E248-4EBB-BC87-0B81F5E257F4Q36574383-5037578B-BD18-4BD3-B57A-5987ADF79BDDQ36963359-A9FC6FB5-8C9C-48B7-A855-3FAC6F11F35CQ37086710-E794AA52-1EA2-4FC5-97E0-96CA74E829F5Q37236636-2BCC24AB-9ECF-4F6F-AE03-E9EFDE96C003Q37261700-7C1D8B18-FA00-4273-96B1-F176309A2E83Q37492464-FBEA7811-D190-4361-9218-6E1999BAA0F2Q37706396-C4CC6F34-8ED8-4A5D-A4B3-DDA5F322AAC6Q38100592-4FFD15EA-F4BA-474F-B95D-2ECF20F51A38Q38259896-69A88ADA-9760-4BA9-BB85-58DAF32ED0AAQ38366556-EA11CA13-79D4-4117-8DCF-C8F25417FB53Q38753386-D19A9F51-F780-423C-AAA5-19C1F877224EQ39030003-F79F8AEA-CA8E-4760-A793-9F50A97028B0Q39130420-C410AB4D-5437-4D13-9F48-43B93EC4E3F0Q39136403-5C4E8C23-3917-4ED3-A4C4-FFDB6D3AD718Q39384440-89866FF8-4344-45D1-878F-9B34FA2900B8
P2860
The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68
description
1997 nî lūn-bûn
@nan
1997 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
The immunodominant antigen of ...... n in the DEAD box helicase p68
@ast
The immunodominant antigen of ...... n in the DEAD box helicase p68
@en
type
label
The immunodominant antigen of ...... n in the DEAD box helicase p68
@ast
The immunodominant antigen of ...... n in the DEAD box helicase p68
@en
prefLabel
The immunodominant antigen of ...... n in the DEAD box helicase p68
@ast
The immunodominant antigen of ...... n in the DEAD box helicase p68
@en
P2093
P2860
P356
P1476
The immunodominant antigen of ...... n in the DEAD box helicase p68
@en
P2093
C T Siegel
H Schreiber
J C Skipper
J Shabanowitz
R C Hendrickson
S C Meredith
P2860
P304
P356
10.1084/JEM.185.4.695
P407
P577
1997-02-01T00:00:00Z